Necessity of selective neck dissection for T1-2N0 TSCC patients: a retrospective cohort study.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Guanzheng Chen, Zhien Feng, Zhengxue Han, Jia Kang, Xiangpan Kong, Bo Li

Ngôn ngữ: eng

Ký hiệu phân loại:

Thông tin xuất bản: England : BMC oral health , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 711768

 BACKGROUND: This study aimed to assess the prognosis of T1-2N0 stage tongue cancer patients who underwent surgery for the primary lesion without elective neck dissection and to identify the risk factors for prognosis. METHODS: We retrospectively analyzed early-stage tongue cancer patients in our center. Statistical analyses were performed using SPSS and R software. RESULTS: The study reviewed 168 patients, revealing a 3-year overall survival rate of 90.5%, a 3-year cervical lymph node metastasis-free survival rate of 73.2%, and a 3-year disease-specific survival rate of 89.3%. A depth of invasion of 3 mm showed significant prognostic value for overall survival (P = 0.001), cervical lymph node metastasis-free survival (P = 0.002), and disease-specific survival (P <
  0.001). Patients were categorized into four subgroups (thick T1, thin T1, thick T2, and thin T2) to further explore the prognostic significance of depth of invasion across different T stage categories. The combination of T stage and a 3 mm depth of invasion demonstrated significant prognostic value in univariate analysis for overall survival (P = 0.002), cervical lymph node metastasis-free survival (P = 0.010), and disease-specific survival (P <
  0.001). COX regression analysis confirmed the statistical significance of T stage combined with a 3 mm depth of invasion for overall survival (OR = 10.653
  95% CI, 2.394 to 47.404
  P = 0.002) and lymph node metastasis-free survival (OR = 3.016
  95% CI, 1.365 to 6.667
  P = 0.006). CONCLUSIONS: The findings highlight depth of invasion and T stage as key prognostic factors in early-stage tongue squamous cell carcinoma. Consideration of elective neck dissection is advised for patients with T2 tumors and a depth of invasion exceeding 3 mm to potentially enhance their prognosis. TRIAL REGISTRATION: The current research was registered in Chinese Clinical Trial Registry on April 8, 2021. The trial registration number is ChiCTR2100045188.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH